MedDataX Logo

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

NCT ID: NCT00910962

Last Updated: 2017-12-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

526 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-08

Study Completion Date

2012-03-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI. Up to approximately 525 subjects will be randomized to meet the MRI recruitment target (90 subjects in substudy.) All subjects will continue to receive the local standard of care for the duration of the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

NSTEMI, acute coronary syndrome, p38 MAPK inhibitor, GW856553, percutaneous coronary intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks

Group Type EXPERIMENTAL

GW856553

Intervention Type DRUG

7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

Treatment B

15 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks

Group Type EXPERIMENTAL

GW856553

Intervention Type DRUG

15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

Treatment C

Placebo twice daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GW856553

7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

Intervention Type DRUG

GW856553

15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID

Intervention Type DRUG

Placebo

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with a NSTEMI, defined as: symptoms (e.g. chest pain, dyspnea) consistent with acute coronary syndrome, lasting at least 10 minutes, with most recent symptoms occurring within the 24 hours prior to presentation, without persistent ST-segment elevation on admission 12-lead ECG, and with Troponin (T or I) above the upper limit of normal (ULN) for the local institution within 18 hours of presentation.
* Subject able to be randomized within 18 hours of presentation.
* Subjects to be managed with an early invasive strategy, with PCI likely to occur at least 2 hours after the start of dosing \[subjects who do not undergo PCI will not be withdrawn from the study\].
* Male or female subject who is 45 years of age or older.
* A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and estradiol less than 40 pg/ml (less than 140 pmol/L) is confirmatory), or child-bearing potential and agrees to use one of the contraception methods listed in the protocol for the duration of dosing and until the first follow-up visit (approximately 2 weeks post last-dose).
* Negative urine or serum pregnancy test (in women of child-bearing potential only).
* Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the first follow-up visit (approximately 2 weeks post last-dose).
* QTcB or QTcF greater than 530 msec.
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria

* History of severe heart failure defined as NYHA class III or IV or those with known severe LV dysfunction \[ejection fraction less than 30%\] regardless of symptomatic status.
* Suspected aortic dissection.
* Severe aortic stenosis or other severe valvular disease.
* Current known life-threatening condition other than vascular disease (e.g. severe chronic airways disease) that may prevent a subject from completing the study.
* Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with active chronic or acute inflammation (e.g. inflammatory bowel disease, osteomyelitis, pneumonia, etc.). Intermittent conditions treated with short-term oral antibiotics (e.g. typical URI) or conditions that are not currently exacerbated (e.g. gout with no current flair) may be included.
* History of myopathy or rhabdomyolysis.
* Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* Known to be Hepatitis B or Hepatitis C positive.
* Current or anticipated use of systemic steroids (oral or IV). Inhaled, intranasal and topical steroids are allowed. A single prophylactic dose of systemic steroid is allowed at time of PCI for subjects with contrast allergy.
* Current or anticipated use of BCRP substrates with a narrow therapeutic index (e.g. daunorubicin, doxorubicin, topotecan, mitoxantrone).
* Previously diagnosed cancer that has not been in complete remission for at least 5 years. Localized carcinomas of the skin and carcinoma in situ of the cervix that have been resected or ablated for cure are not exclusionary..
* Known alcohol or drug abuse within the past 6 months.
* Previous exposure to GW856553.
* Use of another investigational product within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of IP in the current study.
* Any other subject whom the Investigator deems unsuitable for the study (e.g., due to either medical reasons, laboratory abnormalities, expected study medication non-compliance).
* Unwillingness or inability to follow the procedures outlined in the protocol.
* Previous MI or coronary artery bypass graft (CABG) surgery.
* History of kidney transplant or a history of contrast nephropathy.
* Contraindication to MRI scanning (as assessed by local MRI safety questionnaire) which includes but is not limited to: intracranial aneurysm clips or other metallic objects; history of intra-orbital metal fragments that have not been removed by an MD; pacemakers and non-MR compatible heart valves; inner ear implants; history of claustrophobia in MR.
* Allergy to MRI contrast enhancement agent (gadolinium).
* Estimated creatinine clearance by Cockcroft-Gault formula \< 30 mL/min.
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Anchorage, Alaska, United States

Site Status

GSK Investigational Site

Tucson, Arizona, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

Mission Viejo, California, United States

Site Status

GSK Investigational Site

Jacksonville, Florida, United States

Site Status

GSK Investigational Site

St. Petersburg, Florida, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Chicago, Illinois, United States

Site Status

GSK Investigational Site

Indianapolis, Indiana, United States

Site Status

GSK Investigational Site

Iowa City, Iowa, United States

Site Status

GSK Investigational Site

Lexington, Kentucky, United States

Site Status

GSK Investigational Site

Minneapolis, Minnesota, United States

Site Status

GSK Investigational Site

Rochester, Minnesota, United States

Site Status

GSK Investigational Site

Brooklyn, New York, United States

Site Status

GSK Investigational Site

Stony Brook, New York, United States

Site Status

GSK Investigational Site

Durham, North Carolina, United States

Site Status

GSK Investigational Site

Raleigh, North Carolina, United States

Site Status

GSK Investigational Site

Elyria, Ohio, United States

Site Status

GSK Investigational Site

Allentown, Pennsylvania, United States

Site Status

GSK Investigational Site

Camp Hill, Pennsylvania, United States

Site Status

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

GSK Investigational Site

Rapid City, South Dakota, United States

Site Status

GSK Investigational Site

Knoxville, Tennessee, United States

Site Status

GSK Investigational Site

Oak Ridge, Tennessee, United States

Site Status

GSK Investigational Site

Amarillo, Texas, United States

Site Status

GSK Investigational Site

Austin, Texas, United States

Site Status

GSK Investigational Site

Dallas, Texas, United States

Site Status

GSK Investigational Site

Fort Worth, Texas, United States

Site Status

GSK Investigational Site

Round Rock, Texas, United States

Site Status

GSK Investigational Site

Victoria, Texas, United States

Site Status

GSK Investigational Site

Kogarah, New South Wales, Australia

Site Status

GSK Investigational Site

Liverpool, New South Wales, Australia

Site Status

GSK Investigational Site

Brisbane, Queensland, Australia

Site Status

GSK Investigational Site

Bedford Park, South Australia, Australia

Site Status

GSK Investigational Site

Woodville South, South Australia, Australia

Site Status

GSK Investigational Site

Launceston, Tasmania, Australia

Site Status

GSK Investigational Site

Fremantle, Western Australia, Australia

Site Status

GSK Investigational Site

Perth, Western Australia, Australia

Site Status

GSK Investigational Site

Calgary, Alberta, Canada

Site Status

GSK Investigational Site

Montreal, Quebec, Canada

Site Status

GSK Investigational Site

Sainte-Foy, Quebec, Canada

Site Status

GSK Investigational Site

Terrebonne, Quebec, Canada

Site Status

GSK Investigational Site

Bad Krozingen, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Mannheim, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Rastatt, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Ulm, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Potsdam, Brandenburg, Germany

Site Status

GSK Investigational Site

Bad Nauheim, Hesse, Germany

Site Status

GSK Investigational Site

Darmstadt, Hesse, Germany

Site Status

GSK Investigational Site

Frankfurt am Main, Hesse, Germany

Site Status

GSK Investigational Site

Fulda, Hesse, Germany

Site Status

GSK Investigational Site

Limburg an der Lahn, Hesse, Germany

Site Status

GSK Investigational Site

Göttingen, Lower Saxony, Germany

Site Status

GSK Investigational Site

Hanover, Lower Saxony, Germany

Site Status

GSK Investigational Site

Oldenburg, Lower Saxony, Germany

Site Status

GSK Investigational Site

Aachen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bielefeld, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bonn, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Cologne, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Dortmund, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Essen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Leverkusen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Neuss, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Wuppertal, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Worms, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Dresden, Saxony, Germany

Site Status

GSK Investigational Site

Leipzig, Saxony, Germany

Site Status

GSK Investigational Site

Pirna, Saxony, Germany

Site Status

GSK Investigational Site

Halle, Saxony-Anhalt, Germany

Site Status

GSK Investigational Site

Magdeburg, Saxony-Anhalt, Germany

Site Status

GSK Investigational Site

Bad Berka, Thuringia, Germany

Site Status

GSK Investigational Site

Erfurt, Thuringia, Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Berlin, , Germany

Site Status

GSK Investigational Site

Hamburg, , Germany

Site Status

GSK Investigational Site

Hamburg, , Germany

Site Status

GSK Investigational Site

Ahmedabad, , India

Site Status

GSK Investigational Site

Bangalore, , India

Site Status

GSK Investigational Site

Bangalore, , India

Site Status

GSK Investigational Site

Bangalore, , India

Site Status

GSK Investigational Site

Calicut, , India

Site Status

GSK Investigational Site

Pune, , India

Site Status

GSK Investigational Site

Amsterdam, , Netherlands

Site Status

GSK Investigational Site

Amsterdam, , Netherlands

Site Status

GSK Investigational Site

Arnhem, , Netherlands

Site Status

GSK Investigational Site

Nieuwegein, , Netherlands

Site Status

GSK Investigational Site

Tilburg, , Netherlands

Site Status

GSK Investigational Site

Krakow, , Poland

Site Status

GSK Investigational Site

Krakow, , Poland

Site Status

GSK Investigational Site

Krakow, , Poland

Site Status

GSK Investigational Site

Radom, , Poland

Site Status

GSK Investigational Site

Warsaw, , Poland

Site Status

GSK Investigational Site

Alicante, , Spain

Site Status

GSK Investigational Site

Barcelona, , Spain

Site Status

GSK Investigational Site

Jerez (Cadiz), , Spain

Site Status

GSK Investigational Site

Málaga, , Spain

Site Status

GSK Investigational Site

Santiago de Compostela, , Spain

Site Status

GSK Investigational Site

Brighton, East Sussex, , United Kingdom

Site Status

GSK Investigational Site

Bristol, , United Kingdom

Site Status

GSK Investigational Site

Clydebank, , United Kingdom

Site Status

GSK Investigational Site

Edinburgh, , United Kingdom

Site Status

GSK Investigational Site

Leicester, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

Paddington, London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Germany India Netherlands Poland Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140-6736(14)60417-7. Epub 2014 Jun 12.

Reference Type DERIVED
PMID: 24930728 (View on PubMed)

Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, Aylward P, Tanguay JF, DeWinter RJ, Marber MS, Lerman A, Hasselblad V, Granger CB, Newby LK. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am Heart J. 2012 Nov;164(5):646-653.e3. doi: 10.1016/j.ahj.2012.07.030. Epub 2012 Oct 16.

Reference Type DERIVED
PMID: 23137494 (View on PubMed)

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Annotated Case Report Form

View Document

Document Type: Dataset Specification

View Document

Document Type: Clinical Study Report

View Document

Document Type: Individual Participant Data Set

View Document

Document Type: Informed Consent Form

View Document

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.clinicalstudydatarequest.com

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

111810

Identifier Type: -

Identifier Source: org_study_id